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http://dx.doi.org/10.1016/j.kjms.201Abstract Eugenosedin-A (Eu-A) effects on vascular endothelial dysfunction and oxidative
stress in a hyperlipidemic rat model were investigated. Rats were randomly divided into four
groups: two control groups and two treatment groups. The control rats received a regular diet
or high fat diet (HFD); the treatment rats fed received an HFD with 5 mg/kg Eu-A or atorvas-
tatin for 10 weeks. No changes in serotonin levels were observed in the four groups; norepi-
nephrine levels were enhanced in the HFD group which was attenuated by Eu-A and
atorvastatin. In the HFD group, the vascular reactivity was increased by vasoconstrictors (5-
nonyloxytryptamine, 5-HT, and phenylephrine) and decreased by an endothelium-dependent
vasorelaxant, carbachol. Protein levels of a1-adrenergic receptors (not 5-HT1B/2A), reactive ox-
ygen species (ROS) p47phox, p67phox, and gp91phox, and oxidative damage markers 3-
nitrotyrosine (3-NT) and 4-hydroxy-2-nonenal (4-HNE) were increased, but endothelial nitric
oxide synthase (eNOS), P-eNOS and vasodilator-stimulated phosphoprotein phosphorylation
(P-VASP) were decreased. Catalase and superoxide dismutase (SOD-1 and SOD-2) proteins were
increased, but glutathione peroxidase (GPx) was decreased in the aorta. Eu-A and atorvastatins have no conflicts of interest relevant to this article.
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Eugenosedin-A prevents endothelial dysfunction 117reduced vasoconstrictor-induced aortic contractions that might be related to 5-HT1B/2A and a1-
adrenergic receptors inhibitory activities. Eu-A and atorvastatin improved eNOS/P-eNOS, P-
VASP, GPx, and malondialdehyde (MDA) levels, and decreased ROS and oxidative damage
markers. Taken together, we suggest that Eu-A can ameliorate hyperlipidemia-induced
vascular endothelial dysfunction and oxidative dysregulation.
Copyright ª 2013, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Serotonin (5-HT) has been found to augment coronary
arterial constrictor response in patients with coronary
atherosclerosis [1], and its induction of endothelium-
dependent vasorelaxation has been found to be impaired
in atherosclerotic coronary arteries of hypercholesterol-
emic pigs [2]. These findings suggest that endothelial
dysfunction in atherosclerotic arteries may result in
abnormal vascular reactivity to 5-HT. The contributions of
at least two receptor subtypes, 5-HT1B and 5-HT2A, vary
depending on endothelial function and presence of
atherosclerosis lesions [1,3]. Prolonged elevation of plasma
catecholamines contributes to arterial remodeling in
several vascular diseases, including hypertension and
atherosclerosis. The a1-adrenergic system has been impli-
cated in the development of atherosclerotic lesions, and
increases in a1-adrenoceptor caused vasocontraction in
hyperlipidemic rats [4].
Hyperlipidemia impairs endothelial nitric oxide synthase
(eNOS) function and reduces endothelial nitric oxide (NO)
availability in blood vessels [5]. Endothelial dysfunction in
hyperlipidemic vasculature is thought to be an important
cause of increased production of vascular superoxide. The
superoxide causes the activation of nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase and a decline in
expression of eNOS. Hyperlipidemia increases plasma
cholesterol that occurs with concomitant decreases in
plasma NO and endothelium-dependent relaxations in cor-
onary arteries [6,7]. Atorvastatin is one of 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA) reductase in-
hibitors (also called statins) which are widely prescribed to
reduce cholesterol levels in hyperlipidemic patients. Sta-
tins lower cholesterol production and promote hepatic
removal of LDL cholesterol in serum. Aside from their
conventional use to reduce cholesterol levels, statins have
been used in many other clinical conditions [8]. There
is growing evidence that statins may exert additional
pleiotropic effects, including NOS activation, vascular
endothelial protection, antithrombosis, antioxidation, anti-
inflammation and immunomodulation [9,10]. Therefore, we
used atorvastatin as a reference agent in this study.
Polyunsaturated fatty acids of the membrane and lipo-
protein particles are particularly susceptible to free radical
attack, ultimately forming lipid markers of oxidative
damage, as lipid hydroperoxides, lipid hydroxides, hydro-
carbons, and aldehydes [11,12]. 3-Nitrotyrosine (3-NT), 4-
hydroxy-2-nonenal (4-HNE), and malondialdehyde (MDA)
are considered to be biomarkers of oxidative stress and
lipid peroxidation in organisms. In hypercholesterolemia, 3-NT, 4-HNE, and MDA levels are increased [13e15]. Three
anti-oxidative markers catalase, glutathione peroxidase
(GPx), and superoxide dismutase (SOD) have been estab-
lished and utilized in the evaluation of oxidative stress in
animal models of hypertension, diabetes, obesity, and
hyperlipidemia [16,17]. Several studies have shown that
hyperlipidemia and atherosclerosis increase the expression
of catalase, GPx, and SOD and that overexpression of
antioxidant enzymes can scavenge oxidative damage
[18,19]. Other studies, however, show that hyperlipidemia
decreases the expression of catalase, GPx, and SOD,
resulting in accumulations of free radicals and lipid markers
of oxidative damage [14,20].
We previously demonstrated that eugenosedin-A (Eu-A),
a 5-HT1B/2A and a1/a2/b1-adrenergic blocker, was capable
of reducing blood pressure [21], diminishing inflammation,
scavenging free radicals [22], and inhibiting platelet ag-
gregation [23]. Eu-A reduces obesity-related hyperglyce-
mia, hyperinsulinemia, hyperlipidemia [24], and
inflammation [25]. We also proved that Eu-A decreased the
enhancement of adhesion molecules in hyperlipidemic
Sprague-Dawley rats [26]. However, to date, little research
has been undertaken on the 5-HT and a/b adrenergic re-
ceptor antagonistic activities on hyperlipidemia-induced
vascular dysfunctions. In this study, we examine the ac-
tion mechanisms of Eu-A and atorvastatin on vascular and
endothelial functions and oxidative stress in hyperlipidemic
rats.Materials and methods
Animals
Male Sprague-Dawley rats were provided by the National
Laboratory Animal Breeding and Research Center (Taipei,
Taiwan) and housed under constant environmental condi-
tions of temperature and illumination (light between 7:30
AM and 7:30 PM). Water and regular diet were available ad
libitum. After an acclimatization period, the 6-week-old
rats were randomly divided into four groups (two control
groups and two treatment groups) and fed different diets
for 10 weeks. One group of control rats was fed a regular
diet (n Z 8), and the other group of control rats was fed a
high-fat diet (n Z 8) (HFD: cat No. 58G9, TestDiet, Rich-
mond, VA, USA). The HFD contained 60% fat, 21.4% carbo-
hydrates, and 18.6% protein. The treatment groups were
fed HFD supplemented with either Eu-A or atorvastatin
(5 mg/kg). After the rats were killed, parts of thoracic
aorta tissues were used for functional experiments and
118 K.-P. Shen et al.parts were stored in buffer solution at 80C until analysis.
This study was approved by the Animal Care and Use
Committee of Kaohsiung Medical University.
Chemicals and drugs
Eu-A (synthesized in our laboratory) and atorvastatin
(Sigma-Aldrich Chemical Co., St. Louis, MO, USA) were
solubilized in 5% absolute alcohol. Further dilutions of these
agents were made in distilled water.
Functional experiments
The thoracic aorta was quickly removed, cleaned of
adhering fat and connective tissue, and cut into 3e4 mm
wide transverse rings. The rings were then mounted at 1 g
resting tension on stainless steel hooks in a 10 mL organ
bath, bathed at 37C in physiological solution (mM: NaCl
118, KCl 4.8, CaCl2 2.5, MgSO4 1.2, KH2PO4 1.2, NaHCO3 24,
glucose 11), and aerated with a 95% O2 and 5% CO2 mixture.
Isometric tension of the aortic rings was monitored by a
force displacement transducer (UGO BASILE, Model 7004,
Comerio VA, Italy). The tissues were allowed to equilibrate
for 1 hour in physiological solution.
To evaluate the constrictor activity of the thoracic
aorta, cumulative concentration-response curves to 5-
nonyloxytryptamine, 5-HT, and phenylephrine (0.1 nMe10
mM) were constructed in the presence of indomethacin
(10 mM).
In another set of experiments, the effect of NO-
mediated vasorelaxation was examined in the presence of
indomethacin (10 mM). To assess the integrity of the endo-
thelium, thoracic aortas were precontracted with phenyl-
ephrine (10 mM), and a high dose of carbachol (10 mM) was
used to relax the artery rings. Carbachol-induced relaxation
was greater than 80% of the precontracted tone, indicating
that the endothelium was functionally intact. After further
washouts, arteries were precontracted again by phenyl-
ephrine (10 mM) and carbachol was added cumulatively (0.1
nMe10 mM).
Western blot analysis of thoracic aorta tissue
Following previously described procedures [25e27], we
centrifuged the homogenized tissues at 15,000 r/minute for
30 minutes and stored the supernatants at 80C until
further analysis. Aliquots of tissue homogenates were usedTable 1 The sensitivity (pEC50) of 5-nonyloxytryptamine, sero
regular diet, high-fat diet (HFD) or HFD þ agents.
Group 5-Nonyloxytryptamine (pEC50)
Regular diet 5.27  0.15
HFD 5.83  0.22#
HFD þ Eu-A 5.31  0.17*
HFD þ Ator 5.28  0.15*
Values represent the mean  standard error (n Z 8).
Ator Z atorvastatin; Eu-A Z eugenosedin-A.
#p < 0.05 versus regular diet; *p < 0.05 versus HFD.for protein assay (Bio-Rad protein assay reagent) and
Western blot analysis. The aorta tissues were identified by
5-HT1B, 5-HT2A, a1-adrenoceptor, eNOS, P-eNOS, and
vasodilator-stimulated phosphoprotein phosphorylation (P-
VASP) antibody. Oxidative markers were analyzed by
p47phox, p67phox, gp91phox, 3-NT, 4-HNE, and antioxidant
enzymes by catalase, GPx, SOD-1 and SOD-2 antibody
(Santa Cruz Biotechnology, Santa Cruz, CA, USA; 1:500
dilution) and IgG conjugated antibody (Santa Cruz
Biotechnology; 1:10000 dilution). The relative expression of
these proteins in each tissue was quantified by densito-
metric scanning of the western blots using Image-pro plus
software (Media Cybernetics, Silver Spring, MD, USA).
Measurement of plasma serotonin, norepinephrine,
and brain MDA contents
The heparinized blood was centrifuged at 1000 r/minute for
10 minutes. After centrifugation, the serotonin and
norepinephrine levels of plasma were measured by
research assay kits (BAE-5900 and BAE-5200, Labor Diag-
nostika Nord, GmbH & Co, KG, Nordhorn, Germany).
Rat brains were dissected. Homogenates were made in
0.9% saline containing 10 mg/mL tissue. Samples were
centrifuged at 5000 r/minute for 10 minutes. The resulting
supernatant was used to estimate MDA (MDA-586 assay kit,
OxisResearch, Foster City, CA, USA).
Statistical evaluation of data
Results are expressed as mean  standard error (S.E.). One-
way or two-way analysis of variance was used to analyze
differences among multiple comparisons. When appro-
priate, a Tukey-Kramer pairwise comparison was used for
post hoc analysis. A p value < 0.05 was considered signifi-
cant in all experiments. Analysis of data and plotting of
figures were performed using SigmaStat: Version 2.03 and
SigmaPlot: Version 8.0 (Systat Software, Point Richmond,
CA, USA).
Results
Effect of Eu-A on vasocontraction in hyperlipidemic
rats
The thoracic aorta of HFD control group showed increased
sensitivity (as pEC50) to 5-nonyloxytryptamine (pEC50 oftonin, and phenylephrine on thoracic arteries in rats fed a
Serotonin (pEC50) Phenylephrine (pEC50)
5.15  0.24 6.44  0.32
6.49  0.19# 7.85  0.41#
5.07  0.26* 5.94  0.36*
4.97  0.22* 6.31  0.28*
Table 2 The sensitivity (pEC50) and maximum relaxation
(Rmax) of carbachol on thoracic arteries in rats fed a reg-
ular diet, high-fat diet (HFD) or HFD þ agents in the pres-
ence of indomethacin.
Group Carbachol (pEC50) Rmax (%)
Regular diet 7.71  0.11 99  1
HFD 6.69  0.15# 98  0
HFD þ Eu-A 7.22  0.12* 96  2
HFD þ Ator 7.31  0.11* 98  2
Values represent the mean  standard error (n Z 8).
Ator Z atorvastatin; Eu-A Z eugenosedin-A.
#p < 0.05 versus regular diet; *p < 0.05 versus HFD.
Eugenosedin-A prevents endothelial dysfunction 1195-nonyloxytryptamine: HFD, 5.83  0.22 vs. regular diet,
5.27  0.15, n Z 5, p < 0.05) and 5-HT (pEC50 of 5-HT:
HFD, 6.49  0.19 vs. regular diet, 5.15  0.24, n Z 5,
p < 0.05). The vasocontraction by phenylephrine was also
increased in the HFD control group (pEC50 of phenyleph-
rine: HFD, 7.85  0.41 vs. regular diet, 6.44  0.32, nZ 5,
p < 0.05).
In the treatment groups, Eu-A significantly ameliorated
the vasocontraction of thoracic aorta by 5-
nonyloxytryptamine, 5-HT, and phenylephrine. Atorvasta-
tin showed the same effects (Table 1).
Effect of Eu-A on vasorelaxation in hyperlipidemic
rats
To evaluate the HFD-inhibited vascular endothelial relaxa-
tion, carbachol was used in this experiment. The sensitivity
(pEC50) to carbachol in the thoracic aorta of the HFD group
was reduced (pEC50 of carbachol: HFD, 6.69  0.15 vs.
regular diet, 7.71  0.11, n Z 5, p < 0.05). The hyper-
lipidemic rats treated Eu-A and atorvastatin significantly
improved the vasorelaxation by carbachol. However, there
was no marked change in maximum relaxation (Rmax) in
any treatment group (Table 2).α1-receptor
β-actin
5−ΗΤ2Αreceptor
5−ΗΤ1Β receptor
Figure 1. Effect of eugenosedin-A (Eu-A) and atorvastatin (Ator) o
a regular diet (RD) or high-fat diet (HFD). Each value is presented as
versus HFD.5-HT1B/2A and a1 receptor expression in
thoracic aorta
Western blot analysis showed that the untreated HFD group
had 1.3-fold higher expression of a1 receptor in vascular
tissues than the regular diet control group. Eu-A and ator-
vastatin clearly decreased a1 receptor expression in hyper-
lipidemic rats to levels similar to that of the regular diet (RD)
group. However, there were no significant changes in the
expressions of 5-HT1B and 2A receptor in any groups (Fig. 1).
eNOS, P-eNOS, and P-VASP protein expression in
thoracic aorta
Western blot analysis showed that thoracic aorta isolated
from the untreated HFD control group had lower levels of
eNOS (21.7%), P-eNOS (14.6%), and P-VASP (16.8%) proteins
than the regular diet group. Eu-A and atorvastatin pre-
vented the reduction in the expression of those proteins. In
HFD fed rats, Eu-A significantly increased eNOS (15.2%), P-
eNOS (13.2%), and P-VASP (15.6%), and atorvastatin
increased eNOS (14.8%), P-eNOS (15.7%), and P-VASP
(13.7%) (Fig. 2).
p47phox, p67phox, gp91phox, 3-NT, and 4-HNE
expression in the thoracic aorta
Fig. 3 shows the expression of p47phox, p67phox, gp91phox, 3-
NT and 4-HNE protein during differentiation in the thoracic
aorta. The p47phox, p67phox, gp91phox, 3-NT, and 4-HNE
protein expression were increased significantly in the HFD
group compared with the regular diet group. Eu-A and
atorvastatin clearly reduced the overexpression of these
proteins in HFD fed rats.
Catalase, GPx, and SOD protein expression in
thoracic aorta
Compared with the expression of proteins in the two con-
trol groups, the HFD-fed group had significant increases inPr
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Figure 2. Effect of eugenosedin-A (Eu-A) and atorvastatin (Ator) on eNOS, P-eNOS and P-VASP protein expression in thoracic
aorta of rats fed a regular diet (RD) or high-fat diet (HFD). Each value is presented as mean  standard error (n Z 8). #p < 0.05
versus RD; *p < 0.05 versus HFD.
120 K.-P. Shen et al.catalase, SOD-1, and SOD-2, but a decrease in GPx
expression in the aorta (Fig. 4). As shown in Fig. 4, Eu-A and
atorvastatin significantly restored the expression of GPx
protein, but did not affect catalase, or SOD-1 and SOD-2
proteins.
Plasma serotonin, norepinephrine and brain MDA
contents
The concentration of norepinephrine was increased in the
HFD group. Eu-A, like atorvastatin, decreased the HFD-
induced norepinephrine. The levels of serotonin in the four
groups showed no obvious changes. In the two controlp67 phox
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Figure 3. Effect of eugenosedin-A (Eu-A) and atorvastatin (Ator)
thoracic aorta of rats fed a regular diet (RD) or high-fat diet (HFD
#p < 0.05 versus RD; *p < 0.05 versus HFD.groups, the HFD significantly increased the concentration of
MDA (Table 3). Eu-A and atorvastatin treatment reduced
these increases in MDA.Discussion
Eu-A, a 5-HT1B/2Aand a1/a2/b1 adrenergic blocker, has been
shown to ameliorate hyperlipidemia and hyperglycemia in
mice which are fed with an HFD [24]. It also prevented HFD-
induced inflammation and downregulation of eNOS in mice
[25] and improved hyperlipidemia-induced increases of
adhesion molecules in Sprague-Dawley rats [26]. InRD
HFD
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). Each value is presented as mean  standard error (n Z 8).
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Figure 4. Effect of eugenosedin-A (Eu-A) and atorvastatin (Ator) on catalase, GPx, SOD-1, and SOD-2 protein expression in
thoracic aorta of rats fed a regular diet (RD) or high-fat diet (HFD). Each value is presented as mean  standard error (n Z 8).
#p < 0.05 versus RD; *p < 0.05 versus HFD.
Eugenosedin-A prevents endothelial dysfunction 121addition, hyperlipidemia also induced the overexpression of
NADPH oxidases and oxidative proteins contributing to the
decrease of vasorelaxation. Eu-A was able to ameliorate
HFD-induced vascular, endothelial dysfunction and oxida-
tive stress through reducing the protein expression and
activity in a1-adrenoceptor and NADPH oxidases. We sug-
gest that Eu-A inhibition of hyperlipidemia stimulated
norepinephrine release and a1-adrenoceptor expression,
leading to aortic contraction.
Vascular disease-induced smooth muscle cell hypertro-
phy increased the mechanical advantage of the vascular
wall and amplified the contractile potency and efficacy of
the agonist [28]. 5-HT has been found to augment coronary
arterial constrictor response in patients with coronary
atherosclerosis. 5-HT1B and 5-HT2A receptors, upregulated
by atheroma, may mediate the effects of serotonin [1,3].
Ulu et al. [4] demonstrated that, in hyperlipidemia, the
concentrations of catecholamines and a1-adrenoceptor
were upregulated. One previous report also showed that
atorvastatin could affect a-adrenoceptors [28,29]. The
vascular dysfunctions caused by serotonergic and adren-
ergic receptors were related to hyperlipidemia-induced
mitogen-activated protein kinases (MAPKs) and trans-
activation of growth factors [1,4,29,30]. Our study furtherTable 3 Effects of eugenosedin-A (Eu-A) and atorvastatin (Ator
dehyde (MDA) contents in Sprague-Dawley rats fed a high-fat die
Group Norepinephrine (pg/mL)
Regular diet 242.81  11.3
HFD 633.75  20.1#
HFD þ Eu-A 293.15  38.4*
HFD þ Ator 267.25  27.2*
Values represent the mean  standard error (n Z 8).
#p < 0.05 versus regular diet; *p < 0.05 versus HFD.confirmed that the level of norepinephrine, but not sero-
tonin, was enhanced by HFD [4]. The HFD group had higher
vasocontractile activity than the regular diet group that
was stimulated with 5-nonyloxytryptamine (5-HT1B
agonist), 5-HT (5-HT2A agonist), and phenylephrine (a1
agonist). Additionally, the expression of a1 receptors, but
not 5-HT1B and 5-HT2A receptors, was significantly
increased in the thoracic aorta. Therefore, we suggest that
serotonergic receptors contributing to HFD-induced vaso-
contractions could be due to the increases of receptor ac-
tivity, but not protein expression. We also found that Eu-A
and atorvastatin decreased norepinephrine levels and pre-
vented vasocontractions caused by 5-nonyloxytryptamine,
5-HT, and phenylephrine. Meanwhile, the increased a1 re-
ceptor expression recovered to the levels of the RD group
by using Eu-A and atorvastatin (Tables 1 and 3, Fig. 1).
Taken together, we suggest that Eu-A, like atorvastatin,
prevents hyperlipidemia-induced vascular dysfunctions
caused by serotonergic and adrenergic receptors stimula-
tion, which would be involved in the MAPKs pathway, as
described in our previous reports [25,26].
Endothelial cells release both relaxing and contracting
factors that modulate the tone of the underlying smooth
muscle. Endothelium-dependent relaxation is mediated by) on plasma norepinephrine, serotonin, and brain malondial-
t (HFD).
Serotonin (pg/mL) MDA (mM)
68.33  8.26 5.09  0.64
68.17  7.41 49.82  6.73#
74.13  8.09 23.95  3.15*
76.56  8.22 22.43  4.08*
HFD-induced hyperlipidemia
Eugenosedin-A attenuated HFD-induced responses
(-)Vascular endothelial dysfunction
α1-AR/5-HT activity (-) ROS
Oxidative stress (-)
(-)
α1-AR expression, NE level (-)
Carbachol–mediated relaxation 
(Endothelium dependent)
(-)
Figure 5. Proposed mechanism of action of eugenosedin-A
attenuated high-fat diet (HFD)-induced vascular endothelial
dysfunction via inhibition of a1-adrenoceptor (a1-AR)/5-HT
activity and NADPH oxidase expression, and restoration of
carbachol-mediated relaxation.
122 K.-P. Shen et al.multiple factors, including NO, prostacyclin, and an un-
identified non-NO/non-prostanoid endothelium-derived
hyperpolarizing factor. Hypercholesterolemia-increased
plasma cholesterol has also been found to decrease the
endothelium-dependent relaxations in arteries [31].
Impaired eNOS function and endothelial NO availability
associated with hypercholesterolemic vasculature have
been mostly attributed to increases in vascular superoxide
production. Oxidative stress seems to contribute to
hypercholesterolemia-associated endothelium dysfunction
[31,32]. This study focused on NO-mediated vasorelaxation.
After feeding the rats HFD for 10 weeks, we found evidence
of endothelial dysfunction in the rat thoracic aorta, as a
result of decreased NO-mediated vasorelaxation. The eNOS
and P-eNOS proteins were decreased by hyperlipidemia. We
also found reduced expression of P-VASP, a substrate of
protein kinase G. Eu-A and atorvastatin improved the
carbachol-stimulated vasorelaxation, which was impaired
by hyperlipidemia (Table 2). Taken together, the protective
mechanisms of Eu-A and atorvastatin in NO-mediated vas-
orelaxation may be related to reverse the expression of
eNOS, P-eNOS, and P-VASP proteins damaged by hyperlip-
idemia (Fig. 2).
NADPH oxidases are thought to be the major sources of
superoxide production in hypertension, atherosclerosis,
and diabetic vasculature. Previous studies have demon-
strated that hypercholesterolemia increases protein
expression of NADPH oxidase subunits p47phox, p67phox, and
gp91phox, increasing endothelial dysfunction and oxidative
stress [33,34]. 3-NT has been identified as an oxidative
stress, as well as of the production of NO [35]. 4-HNE is an
oxidized product from polyunsaturated fatty acids [36].
MDA is an end product of polyunsaturated fatty acid per-
oxidation [37]. In our study, hyperlipidemia was found to
increase protein expression of NADPH oxidase subunits
p47phox, p67phox, and gp91phox in the thoracic aorta (Fig. 3),
as well as protein expression of 3-NT and 4-HNE (Fig. 4).
MDA was also increased in brain tissues (Table 3). Groups
pretreated with Eu-A and atorvastatin did not develop ab-
normalities in protein expressions of p47phox, p67phox,
gp91phox, 3-NT, and 4-HNE in the thoracic aorta. The
increased MDA concentrations were obviously reduced by
Eu-A and atorvastatin. These findings suggest that the
mechanism through which Eu-A and atorvastatin ameliorate
the dysfunction of endothelium in hyperlipidemic rats was
related to decreases in the production of superoxide.
Some antioxidant enzymes, mainly catalase, GPx, and
SOD, are known to control oxidative damage. Catalase
catalyzes the decomposition of H2O2 to H2O and O2; and
GPx effectively inhibits peroxynitrite-mediated oxidation
and protects against the formation of protein 3-NT. Simi-
larly, SOD removes the superoxide (O2
e) radical, repairs
cells, and reduces the damage caused by superoxide
[20,38,39]. Some studies have established that over-
expression of antioxidant enzymes could scavenge oxida-
tive damage in hyperlipidemia [18,19], while others report
that the expression of antioxidant enzymes is decreased in
hyperlipidemia [14,20]. In the present study, we found in-
creases of catalase, SOD-1, and SOD-2 and decreases of GPx
in the HFD group. Eu-A and atorvastatin restored the
expression of antioxidant enzyme GPx in the aorta. Eu-A
has been proven to have antioxidant activity similar tothat of ascorbic acid [40]. Therefore, we suggest that Eu-A
prevention of vascular endothelial dysfunction occurs
through decreases of oxidative stress and restoration of
antioxidant enzymes.Conclusions
Through its attenuation of a1-adrenoceptor/5-HT activity
and NADPH oxidase, and restoration of carbachol-mediated
relaxation, Eu-A inhibited HFD-induced vascular and endo-
thelial dysfunction, and oxidative stress (Fig. 5). Based on
the findings of this study, we suggest that Eu-A could be
used to control HFD-induced metabolic syndrome.Acknowledgments
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